Arca
Skip to content

Cognitive Dysfunction

Drug research and approvals for cognitive Dysfunction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 847 studies of cognitive Dysfunction are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 847
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 847 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

4 approved, 15 in phase 3, 42 in phase 2, 33 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Flortaucipir, Florbetaben, Florbetapir, Flutemetamol

Donepezil
Phase 3 Acetylcholinesterase inhibitor
Metformin
Phase 3 Mitochondrial complex I (NADH dehydrogenase) inhibitor
Atorvastatin
Phase 3 HMG-CoA reductase inhibitor
Memantine
Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
Bexarotene
Phase 3 Retinoid X receptor agonist
Duloxetine
Phase 3 Serotonin transporter inhibitor
Quetiapine
Phase 3 Serotonin 2a (5-HT2a) receptor antagonist
Raloxifene
Phase 3 Estrogen receptor beta modulator
Tamoxifen
Phase 3 Estrogen receptor alpha modulator
Sertindole
Phase 3 Dopamine D2 receptor antagonist
Cholecalciferol
Phase 3 Vitamin D receptor agonist
Galantamine
Phase 3 Acetylcholinesterase inhibitor
Rivastigmine
Phase 3 Cholinesterases; ACHE & BCHE inhibitor
Solanezumab
Phase 3 Amyloid-beta A4 protein binding agent
Acetylcysteine
Phase 2 Glutathione precursor
Curcumin
Phase 2
Human immunoglobulin g
Phase 2 Replacement therapy, immunomodulatory effects
Levetiracetam
Phase 2 Synaptic vesicle glycoprotein 2A modulator
Encenicline
Phase 2 Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist
Davunetide
Phase 2 Tubulin stabiliser
Cannabidiol
Phase 2 Cannabinoid CB1 receptor negative allosteric modulator
Peptide t
Phase 2
Ibuprofen
Phase 2 Cyclooxygenase inhibitor
Lamotrigine
Phase 2 Sodium channel alpha subunit blocker
Maraviroc
Phase 2 C-C chemokine receptor type 5 antagonist
Norepinephrine
Phase 2 Adrenergic receptor agonist
Pioglitazone
Phase 2 Peroxisome proliferator-activated receptor gamma agonist
Rosiglitazone
Phase 2 Peroxisome proliferator-activated receptor gamma agonist
Atomoxetine
Phase 2 Norepinephrine transporter inhibitor

Showing the 30 furthest along of 90 in trials.

How Its Trials Ended

3,264 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 449 whose ending is known, 37% met their primary endpoint, 11% missed it and 51% stopped early.

  • Completed, result not reported1,25839%
  • Ongoing1,05232%
  • Status unknown50515%
  • Met its primary endpoint1685%
  • Stopped: other or unclear1324%
  • Stopped: enrollment or feasibility542%
  • Missed its primary endpoint512%
  • Stopped: funding191%
  • Stopped: lack of efficacy171%
  • Stopped: sponsor or business decision80%

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Nov 4, 1991Pramiracetam SulfateFor the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.Cambridge Neuroscience, Inc.Designated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Apr 15, 2025LeqembiLecanemabEisai GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.